Nuvectis Pharma Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Selling, General & Admin	7.52	7.52	6.01	3.35	0.01
Research & Development	15.67	15.38	13.23	9.55	0
Operating Expenses	23.19	22.9	19.23	12.89	0.01
Operating Income	-23.19	-22.9	-19.23	-12.89	-0.01
Other Expense / Income	-0.81	-0.64	-0.15	-0	-
Pretax Income	-22.38	-22.26	-19.09	-12.89	-0.01
Net Income	-22.38	-22.26	-19.09	-12.89	-0.01
Shares Outstanding (Basic)	17	16	13	4	0
Shares Outstanding (Diluted)	17	16	13	4	0
Shares Change	12.46%	22.90%	196.55%	4168.28%	-
EPS (Basic)	-1.41	-1.43	-1.51	-3.02	-0.10
EPS (Diluted)	-1.41	-1.43	-1.51	-3.02	-0.10
Free Cash Flow	-15.54	-15.95	-13.56	-9.5	0
Free Cash Flow Per Share	-0.94	-1.03	-1.07	-2.23	-
EBITDA	-22.38	-22.26	-19.09	-12.89	-0.01
EBIT	-22.38	-22.26	-19.09	-12.89	-0.01

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).